SCHEDULE 13G: Pathstone Family Office Discloses 7.91% Stake in NKGen Biotech

Pathstone Family Office, LLC has filed a Schedule 13G, reporting beneficial ownership of 7.91% of NKGen Biotech, Inc.'s common stock as of October 17, 2024.

Summary

• PATHSTONE FAMILY OFFICE, LLC, a Delaware-based investment adviser, has filed a Schedule 13G.
• The filing indicates beneficial ownership of 2,797,661 shares of NKGen Biotech, Inc.'s Common Stock.
• This stake represents 7.91% of the total class of securities.
• The shares are held with shared dispositive power, meaning Pathstone Family Office, LLC can direct the sale of these shares on behalf of a client.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of NKGen Biotech, Inc.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing (Schedule 13G) reporting beneficial ownership. It is neutral in tone and does not convey positive or negative sentiment regarding the issuer's performance or outlook.

Risks

• The document does not detail specific risks related to NKGen Biotech, Inc.'s operations or financial health, as it is a beneficial ownership report.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding NKGen Biotech, Inc.'s future performance or operations.

Industry Context

This filing is a routine disclosure required by the SEC when an entity acquires beneficial ownership of more than 5% of a company's stock. For the investment management industry, it signifies a significant position taken by a family office on behalf of its clients, indicating their investment interest in the biotech sector, specifically NKGen Biotech. It does not provide insights into broader industry trends beyond the fact that investment firms are actively managing portfolios within the sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can be a signal of confidence or interest.
• Investment Professionals: Offers data points for tracking institutional ownership and potential liquidity in the stock.

Key Dates

Keywords

NKGen Biotech, Pathstone Family Office, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Biotech, Healthcare